Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Warren Fiskus

Showing results (41-50 of 94) with videos related to

Pageof 10
Sort By:
Cancer Biology & Therapy|March 13, 2009
Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cellsWarren Fiskus, Kate Buckley, Rekha Rao, et al.
Blood|July 29, 2008
Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cellsWarren Fiskus, Rekha Rao, Pravina Fernandez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2011
Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cellsWarren Fiskus, Srdan Verstovsek, Taghi Manshouri, et al.
Oncotarget|July 16, 2014
Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cellsKyungsoo Ha, Warren Fiskus, Dong Soon Choi, et al.
Blood Cancer Journal|February 1, 2022
Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cellsWarren Fiskus, Taghi Manshouri, Christine Birdwell, et al.
Cancer Research|September 5, 2019
Correction: Androgen Receptor Is the Key Transcriptional Mediator of the Tumor Suppressor SPOP in Prostate CancerChuandong Geng, Kimal Rajapakshe, Shrijal S Shah, et al.
Cancer Biology & Therapy|May 15, 2009
Co-treatment with heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (DMAG) and vorinostat: a highly active combination against human mantle cell lymphoma (MCL) cellsRekha Rao, Pearl Lee, Warren Fiskus, et al.
Cancer Research|October 3, 2014
Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancerChuandong Geng, Kimal Rajapakshe, Shrijal S Shah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2008
Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cellsWarren Fiskus, Yongchao Wang, Rajeshree Joshi, et al.
Cancer Research|August 10, 2016
SIRT2 Deacetylates and Inhibits the Peroxidase Activity of Peroxiredoxin-1 to Sensitize Breast Cancer Cells to Oxidant Stress-Inducing AgentsWarren Fiskus, Veena Coothankandaswamy, Jianguang Chen, et al.
Pageof 10

Showing results (41-50 of 94) with videos related to

Sort By:
Pageof 10
Cancer Biology & Therapy|March 13, 2009
Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cellsWarren Fiskus, Kate Buckley, Rekha Rao, et al.
Blood|July 29, 2008
Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cellsWarren Fiskus, Rekha Rao, Pravina Fernandez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2011
Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cellsWarren Fiskus, Srdan Verstovsek, Taghi Manshouri, et al.
Oncotarget|July 16, 2014
Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cellsKyungsoo Ha, Warren Fiskus, Dong Soon Choi, et al.
Blood Cancer Journal|February 1, 2022
Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cellsWarren Fiskus, Taghi Manshouri, Christine Birdwell, et al.
Cancer Research|September 5, 2019
Correction: Androgen Receptor Is the Key Transcriptional Mediator of the Tumor Suppressor SPOP in Prostate CancerChuandong Geng, Kimal Rajapakshe, Shrijal S Shah, et al.
Cancer Biology & Therapy|May 15, 2009
Co-treatment with heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (DMAG) and vorinostat: a highly active combination against human mantle cell lymphoma (MCL) cellsRekha Rao, Pearl Lee, Warren Fiskus, et al.
Cancer Research|October 3, 2014
Androgen receptor is the key transcriptional mediator of the tumor suppressor SPOP in prostate cancerChuandong Geng, Kimal Rajapakshe, Shrijal S Shah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2008
Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cellsWarren Fiskus, Yongchao Wang, Rajeshree Joshi, et al.
Cancer Research|August 10, 2016
SIRT2 Deacetylates and Inhibits the Peroxidase Activity of Peroxiredoxin-1 to Sensitize Breast Cancer Cells to Oxidant Stress-Inducing AgentsWarren Fiskus, Veena Coothankandaswamy, Jianguang Chen, et al.
Pageof 10